Patent · US Active

Recombinant bispecific antibody binding to CD20 and CD95

US10590202B2 · kind B2 · utility

0Cited by

2References

10Claims

0Family size

Assignee

BALIOPHARMA AG · CH

Inventors

Andreas Herrmann · Stuttgart, DE
Ludger Grosse-Hovest · Tübingen, DE

Key dates

Filing date	Nov 19, 2013
Grant date	Mar 17, 2020
Priority date	—
Expiry date	Apr 25, 2035

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2319/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

A bispecific antibody format, which comprises a) a Fab fragment comprising a first binding site for a first antigen; b) an scFv fragment comprising a second binding site for a second antigen; and c) a CH2 domain, wherein the Fab fragment and the scFv fragment are linked via the CH2 domain, wherein the first antigen is CD95 and the second antigen is CD20; or the first antigen is CD20 and the second antigen is CD95.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.